Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya K
Department of Developmental Biology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.
Genes Chromosomes Cancer. 1999 Jun;25(2):176-83.
The Wilms' tumor gene WT1, whose loss of function accounts for the genesis of about 10% of Wilms' tumors, is expressed in hematopoietic stem cells and leukemia. By analogy with the relationship between the kidney stem cell and Wilms' tumor, it is probable that WT1 is mutated in leukemia. WT1 mutations have been found in only eight cases of primary leukemia, mainly in acute myeloid leukemia (AML) and rarely in acute lymphoblastic leukemia. However, two other studies have demonstrated the absence of WT1 mutations in leukemia. To determine if WT1 mutations are associated with leukemias, we screened childhood nonlymphoid malignancies for WT1 mutation. WT1 mutations were found in 6 of 46 (13%) AMLs, but not in other nonlymphoid hematological malignancies. In addition, the presence of WT1 mutations in AML caused by chromosomal translocations suggests that mutations of WT1 may lead to the progression of leukemia.
威尔姆斯瘤基因WT1在造血干细胞和白血病中表达,其功能丧失约占威尔姆斯瘤发病原因的10%。类比肾干细胞与威尔姆斯瘤的关系,WT1很可能在白血病中发生了突变。仅在8例原发性白血病中发现了WT1突变,主要见于急性髓系白血病(AML),急性淋巴细胞白血病中罕见。然而,另外两项研究表明白血病中不存在WT1突变。为了确定WT1突变是否与白血病相关,我们筛查了儿童非淋巴细胞恶性肿瘤中的WT1突变。在46例AML中有6例(13%)发现了WT1突变,但在其他非淋巴细胞血液系统恶性肿瘤中未发现。此外,由染色体易位引起的AML中存在WT1突变表明,WT1突变可能导致白血病进展。